Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 133
Selected: 0
NCT IDTitle
NCT00319735Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
NCT01074970PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
NCT05502315Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT00216125Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
NCT01780545Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT02500121Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
NCT01624493BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
NCT04589832Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
NCT04289779Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT04848337Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT02581059Efficacy of Ginseng for Patients on Regorafenib
NCT01485874Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
NCT00890955Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
NCT00572572Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
NCT01732107Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
NCT03099564Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
NCT01736917Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT00216073Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
NCT04711824Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT00537173Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
NCT07185945Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
NCT03871153Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
NCT00613626Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT06809140Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
NCT06503614A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
NCT06392841Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
NCT06835387Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
NCT00216021Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
NCT03552380Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
NCT03272217Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
NCT05852717Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT02500901Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
NCT00216112Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
NCT05956041Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
NCT03448718Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
NCT00216086Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
NCT04886531Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT00706641Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT00732303Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
NCT03558087Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
NCT05406713Pembrolizumab in Muscle-invasive Bladder Cancer
NCT03557918Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
NCT05467891Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT00632541A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
NCT02343952Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
NCT00216138Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
NCT00317200A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
NCT03783936Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC